Moderna R&D Day Highlights Progress and Strategic Priorities
WEBSep 12, 2024 · Looking ahead to 2026-2028, Moderna will expand its commercial portfolio with first-in-class vaccines and therapeutics to address non-respiratory diseases, including cytomegalovirus, norovirus, propionic acidemia, methylmalonic acidemia, and melanoma.
Moderna R&D Day Highlights Progress and Strategic Priorities
WEBSep 12, 2024 · Updates and extends financial framework through 2028. CAMBRIDGE, MA / ACCESSWIRE / September 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced program and financial updates demonstrating progress and strategic prioritization of its mRNA pipeline at its annual R&D Day event. The updates include data readouts in the Company’s respiratory ...
Moderna R&D Day Highlights Progress and Strategic Priorities
WEBSep 12, 2024 · Implements portfolio prioritization and cost efficiencies to reduce R&D expense by $1.1 billion, from $4.8 billion in 2024E to $3.6-3.8 billion in 2027. Updates and extends financial framework ...
Moderna to Host Investor Event - R&D Day and Business Updates
WEBAug 30, 2023 · CAMBRIDGE, MA / ACCESSWIRE / August 30, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 1:00 p.m. ET on Wednesday, September 13, 2023.
Novartis R&D day spotlights attractive growth profile, …
WEBDec 2, 2021 · New announcements at R&D Day 2021: Cosentyx, our largest medicine by sales, showed topline results in moderate to severe hidradenitis suppurativa (HS), a potential new indication.
MRNA - Moderna R&D Day Highlights Progress and Strategic...
WEBSep 12, 2024 · Moderna, Inc. held its annual R&D Day on September 12, 2024, to outline its progress and strategic priorities moving forward. Highlighting an ambitious pipeline, the company aims for ten product approvals by 2027, and expects regulatory submissions for both a next-generation COVID-19 vaccine and a flu/COVID combination vaccine in 2024.
Novartis upgrades mid-term sales growth guidance, showcases its ...
WEBNov 28, 2023 · Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day. Ad hoc announcement pursuant to Art. 53 LR. Basel, November 28, 2023 — Novartis executives are meeting investors and analysts today at an event in London, U.K., to showcase the company’s ‘pure play ...
D Day Highlights Modernaâ
WEBAt Moderna’s sixth annual Research & Development Day, presentations from CEO Stéphane Bancel, President Stephen Hoge, M.D., and Moderna clinical team leaders discussed the organization’s advances across a portfolio of mRNA programs. The 2022 R&D Day sessions focused on Phase 3 trials and programs currently dosing in …
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
WEBSep 8, 2022 · Moderna's Phase 2 clinical trial will determine if mRNA-4157 in combination with KEYTRUDA®, an approved cancer therapy, can improve recurrence-free survival (at 12 months) in patients with resected melanoma at high risk of recurrence, compared to KEYTRUDA alone.
Novartis R&D day spotlights attractive growth profile,
WEBDec 2, 2021 · New announcements at R&D Day 2021: Cosentyx, our largest medicine by sales, showed topline results in moderate to severe hidradenitis suppurativa (HS), a potential new indication.